16 September 2026 editorial review · Trial
Allogeneic regenerative islet transplantation for brittle T1D: review notes
These notes document the scope actually reviewed, including source-access limits. They are not independent clinical certification or a guarantee that every claim was verified.
Read the trial evidence page →Baseline trial evidence review: A–H
Outcome: Expanded sparse summary/eligibility using current registry design, inclusion criteria and primary outcome; no efficacy inferred from registration.
Registry: NCT06196996. Registered endpoint checked: Time in Range (up to 12 months); HbA1c (up to 12 months); C-peptide (up to 12 months); insulin (up to 12 months). Eligibility check: Registry age 6 Years to 65 Years; substantive diagnosis/stage, device and other inclusion restrictions were compared with the public eligibility summary. The registry remains the source for full exclusions. Limits: No usable primary abstract was independently recovered in this pass for this record. Protocol/design wording was assessed; any existing detailed sponsor, conference or historical outcome claims require their cited source and were not independently certified through full-text review.